Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medtronic (MDT – Research Report), Daré Bioscience (DARE – Research Report) and Bolt Biotherapeutics (BOLT – Research Report).
Daré Bioscience (DARE)
In a report released yesterday, Kemp Dolliver from Brookline Capital Markets reiterated a Buy rating on Daré Bioscience, with a price target of $3.00. The company’s shares closed last Tuesday at $0.32, close to its 52-week low of $0.27.
According to TipRanks.com, Dolliver is ranked #6145 out of 8848 analysts.
Currently, the analyst consensus on Daré Bioscience is a Strong Buy with an average price target of $3.67, which is a 1083.9% upside from current levels. In a report issued on May 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $6.00 price target.
Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics received a Hold rating and a $1.50 price target from Stifel Nicolaus analyst Stephen Willey yesterday. The company’s shares closed last Tuesday at $1.32.
According to TipRanks.com, Willey is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Bolt Biotherapeutics with a $6.50 average price target, implying a 396.2% upside from current levels. In a report released yesterday, Guggenheim also downgraded the stock to Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MDT:
- Medtronic Diabetes, Arecor establish collaboration for thermostable insulin
- AtriCure price target lowered to $49 from $57 at Canaccord
- Medtronic announces approval of Inceptiv closed-loop rechargeable SCS by FDA
- Oppenheimer medical devices analysts hold analyst/industry conference call
- Integer upgraded to Buy from Neutral at BofA
